Physician profile
Max A Shapiro
NPI 1770768780
$12,242.60
in general payments reported to CMS, 2019-2025
34 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $493 · 2021: $1,066 · 2022: $3,026 · 2023: $1,829 · 2024: $2,403 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,829 · Education: $35.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,828.62 |
| Education | $35.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,161.86 | 2022-2025 | |
| Abbvie INC. | $1,950.08 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,686.58 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $833.17 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $812.24 | 2019-2025 | |
| Lilly USA, LLC | $678.42 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $659.64 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $567.36 | 2022-2025 | Dupixent |
| Celgene Corporation | $500.30 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $338.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $239.22 | 2022-2025 | Ocaliva |
| Organon LLC | $217.94 | 2023-2025 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $198.01 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $145.81 | 2022-2024 | Dificid, Zinplava |
| Ars Pharmaceuticals Operations, INC. | $124.98 | 2025 | Neffy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $113.19 | 2020-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $111.78 | 2019-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $108.17 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $106.57 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $105.38 | 2019-2022 | |
| Celltrion USA INC. | $93.99 | 2024-2025 | Vegzelma, Zymfentra |
| Allergan, INC. | $84.75 | 2019-2020 | |
| Medtronic, INC. | $59.25 | 2023-2025 | Interstim, Pillcam |
| Aimmune Therapeutics, INC. | $54.29 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $53.05 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $48.46 | 2022-2023 | Injectafer |
| Blueprint Medicines Corporation | $43.28 | 2023 | |
| Gilead Sciences, INC. | $42.23 | 2022-2025 | |
| Redhill Biopharma INC. | $26.26 | 2021 | |
| Vivus LLC | $20.43 | 2022 | |
| Medline Industries LP | $17.14 | 2023 | |
| Olympus America INC. | $14.06 | 2023 | Disposable Emr Kit |
| Micro-Tech Endoscopy USA, INC. | $13.34 | 2023 | Lesionhunter |
| Fresenius Kabi USA, LLC | $13.07 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.